22 May 2013
Keywords: insite, sell, isv-403, bausch, lomb, vision, its
Article | 05 January 2004
InSite Vision is to sell its drug candidate ISV-403, indicated for thetreatment of ocular infections, to Bausch & Lomb. Under the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
10 November 2003
24 May 2004
21 May 2013
© 2013 thepharmaletter.com